Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hewson, S. Patel, L. Calzetta, H. Campwala, S. Havard, E. Luscombe, P. Clarke, P. Peachell, M. Matera, M. Cazzola, C. Page, W. Abraham, C. Williams, J. Clark, N. Clarke, M. Yeadon (Sandwich, Sheffield, London, United Kingdom; Rome, Naples, Italy; Miami Beach, Cambridge, United States Of America). Late-breaking abstract: Preclinical evaluation of an inhibitor of cytosolic phospholipase A₂α for the treatment of asthma. Eur Respir J 2011; 38: Suppl. 55, 4498

Member's Comments

No comment yet.

Related content which might interest you: Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 Safety and pharmacology of a soluble epoxide hydrolase inhibitor Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Late-breaking abstract: Pre-clinical efficacy of RP5090 in PI3Kδ mediated airway disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 SPARTA: Efficacy and safety assessment of two regimens of alpha1-proteinase inhibitor in emphysema due to alpha1-antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Regulation and overexpression of 85-kDa cytosolic phospholipase A2 in asthma Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Late-breaking abstract: Genome-wide association of GLCCI1 with asthma steroid treatment response Source: Annual Congress 2011 - Phenotyping asthma: a clue for treatments? Year: 2011 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 AZD9668: Pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE) Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010 Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1-proteinase inhibitor in alpha1-antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013